We evaluated the anti-proliferative activity of palbociclib, the first approved CDK4/6 inhibitor for the treatment of patients with HR-positve, HER2-negative breast cancer, in these 6 lines of ESCC cells. This evidence concerns the gene CDK4 and breast carcinoma.